ATE493442T1 - Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie - Google Patents
Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapieInfo
- Publication number
- ATE493442T1 ATE493442T1 AT05852441T AT05852441T ATE493442T1 AT E493442 T1 ATE493442 T1 AT E493442T1 AT 05852441 T AT05852441 T AT 05852441T AT 05852441 T AT05852441 T AT 05852441T AT E493442 T1 ATE493442 T1 AT E493442T1
- Authority
- AT
- Austria
- Prior art keywords
- patients
- selection
- igf1r
- biological markers
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63315604P | 2004-12-03 | 2004-12-03 | |
PCT/US2005/043184 WO2006060419A2 (en) | 2004-12-03 | 2005-11-30 | Biomarkers for pre-selection of patients for anti-igf1r therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE493442T1 true ATE493442T1 (de) | 2011-01-15 |
Family
ID=36190453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT05852441T ATE493442T1 (de) | 2004-12-03 | 2005-11-30 | Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie |
Country Status (11)
Country | Link |
---|---|
US (1) | US7811562B2 (de) |
EP (3) | EP1828249B1 (de) |
JP (3) | JP2008521907A (de) |
AT (1) | ATE493442T1 (de) |
CA (1) | CA2589885A1 (de) |
DE (1) | DE602005025685D1 (de) |
ES (1) | ES2356830T3 (de) |
MX (1) | MX2007006640A (de) |
PT (1) | PT1828249E (de) |
TW (1) | TWI376233B (de) |
WO (1) | WO2006060419A2 (de) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080193445A1 (en) * | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
JP4563171B2 (ja) * | 2002-05-24 | 2010-10-13 | シェーリング コーポレイション | 中和ヒト抗igfr抗体 |
CA2490280A1 (en) * | 2002-07-01 | 2004-01-08 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
WO2005016970A2 (en) | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
EP2360279A1 (de) | 2005-04-14 | 2011-08-24 | Trustees Of Boston University | Diagnose für Lungenerkrankungen mittels Klassenvorhersage |
JP4875064B2 (ja) * | 2005-04-15 | 2012-02-15 | シェーリング コーポレイション | 癌を処置または予防するための方法および組成物 |
BRPI0611984A2 (pt) | 2005-06-17 | 2009-07-07 | Imclone Systems Inc | uso de anticorpos igf-ir para fabricação de um medicamento para tratar um tumor ósseo |
EP1926996B1 (de) | 2005-09-20 | 2011-11-09 | OSI Pharmaceuticals, Inc. | Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren |
JP5198289B2 (ja) | 2006-02-03 | 2013-05-15 | イムクローン・リミテッド・ライアビリティ・カンパニー | 前立腺癌の治療用アジュバントとしてのigf−irアンタゴニスト |
WO2007093008A1 (en) * | 2006-02-17 | 2007-08-23 | Adelaide Research & Innovation Pty Ltd | Antibodies to insulin-like growth factor i receptor |
EP2605018A1 (de) | 2006-03-09 | 2013-06-19 | The Trustees of the Boston University | Diagnose- und Prognoseverfahren für Lungenerkrankungen mittels Genexpressionsprofilen aus Nasenepithelzellen |
EP2405270B1 (de) * | 2006-06-30 | 2013-07-17 | Merck Sharp & Dohme Corp. | IGFBP2-Biomarker |
US20100120055A1 (en) * | 2006-09-28 | 2010-05-13 | Cell Signaling Technology, Inc. | Tyrosine phosphorylation sites |
AU2007334456A1 (en) * | 2006-12-13 | 2008-06-26 | Merck Sharp & Dohme Corp. | Methods of cancer treatment with IGF1R inhibitors |
WO2008144345A2 (en) * | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
AU2008282863A1 (en) * | 2007-07-31 | 2009-02-05 | Merck Sharp & Dohme Corp. | IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders |
EP2193211A4 (de) * | 2007-09-19 | 2010-12-08 | Univ Boston | Identfizierung neuer wege zur wirkstoffentwicklung für lungenleiden |
WO2009045389A2 (en) * | 2007-10-03 | 2009-04-09 | Osi Pharmaceuticals, Inc. | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
EP2201378A2 (de) * | 2007-10-03 | 2010-06-30 | OSI Pharmaceuticals, Inc. | Biologische marker als prädiktoren der antikrebsreaktion auf insulinähnlichen wachstumsfaktor-1-rezeptor-kinaseinhibitoren |
US20110091524A1 (en) * | 2007-12-18 | 2011-04-21 | Yan Wang | Biomarkers for sensitivity to anti-igf1r therapy |
SG171724A1 (en) * | 2008-11-12 | 2011-07-28 | Schering Corp | ßGI-IGG INTRON FOR ENHANCED ANTI-IGF1 R EXPRESSION |
US20110171124A1 (en) * | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
WO2010146059A2 (en) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarkers for igf-1r inhibitor therapy |
EP2494070A2 (de) * | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Verfahren zur krebsbehandlung bei patienten mit igf-1r-hemmer-resistenz |
CN105699638B (zh) | 2009-10-30 | 2018-05-22 | 学校法人庆应义塾 | 抗癌剂感受性的判定方法 |
ES2786753T3 (es) | 2009-12-22 | 2020-10-13 | Expression Pathology Inc | Ensayo de SRM/MRM de la proteína del sustrato 1 del receptor de insulina (IRS1) |
CA2783656A1 (en) | 2010-03-03 | 2011-09-09 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2011223655A1 (en) * | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
KR20130048242A (ko) | 2010-07-22 | 2013-05-09 | 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 | 항-종양 항원 항체 및 이용 방법 |
TW201302793A (zh) * | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
CA2825894C (en) | 2011-02-02 | 2021-11-30 | Amgen Inc. | Prognosis of cancer using a circulating biomarker |
WO2012116040A1 (en) | 2011-02-22 | 2012-08-30 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
JP2014519813A (ja) | 2011-04-25 | 2014-08-21 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 癌薬剤発見、診断、および治療におけるemt遺伝子シグネチャーの使用 |
US20140309229A1 (en) * | 2011-10-13 | 2014-10-16 | Bristol-Myers Squibb Company | Methods for selecting and treating cancer in patients with igf-1r/ir inhibitors |
US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
CN114606309A (zh) | 2014-11-05 | 2022-06-10 | 威拉赛特公司 | 使用机器学习和高维转录数据的诊断系统和方法 |
CN107614010A (zh) | 2015-03-09 | 2018-01-19 | 艾更斯司股份有限公司 | 结合至flt3蛋白的抗体药物偶联物(adc) |
WO2018009915A1 (en) | 2016-07-08 | 2018-01-11 | Trustees Of Boston University | Gene expression-based biomarker for the detection and monitoring of bronchial premalignant lesions |
JP2023520821A (ja) * | 2020-04-08 | 2023-05-19 | アリアダ セラピューティクス,インコーポレイテッド | 血液脳関門送達のための組成物および方法 |
TW202320850A (zh) * | 2021-08-10 | 2023-06-01 | 美商維里迪恩醫療股份有限公司 | 用於治療甲狀腺眼病之組合物、劑量及方法 |
Family Cites Families (135)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
US3817837A (en) | 1971-05-14 | 1974-06-18 | Syva Corp | Enzyme amplification assay |
US3939350A (en) | 1974-04-29 | 1976-02-17 | Board Of Trustees Of The Leland Stanford Junior University | Fluorescent immunoassay employing total reflection for activation |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
US4277437A (en) | 1978-04-05 | 1981-07-07 | Syva Company | Kit for carrying out chemically induced fluorescence immunoassay |
US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4543439A (en) | 1982-12-13 | 1985-09-24 | Massachusetts Institute Of Technology | Production and use of monoclonal antibodies to phosphotyrosine-containing proteins |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5534617A (en) | 1988-10-28 | 1996-07-09 | Genentech, Inc. | Human growth hormone variants having greater affinity for human growth hormone receptor at site 1 |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5977307A (en) | 1989-09-07 | 1999-11-02 | Alkermes, Inc. | Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins |
WO1991004014A1 (en) | 1989-09-21 | 1991-04-04 | Synergen, Inc. | Method for transporting compositions across the blood brain barrier |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
CA2058041A1 (en) | 1990-06-27 | 1991-12-28 | Katsuichi Sakano | Anti-igf-ii monoclonal antibody |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5198340A (en) | 1991-01-17 | 1993-03-30 | Genentech, Inc. | Assay for free igf-i, igf-ii, and gh levels in body fluids |
US5262308A (en) | 1992-01-28 | 1993-11-16 | Thomas Jefferson University | Cell lines which constitutively express IGF-1 and IGF-1 R |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
ATE191853T1 (de) | 1992-07-27 | 2000-05-15 | Us Health | Zielgerichte liposome zur blut-hirne schranke |
WO1994023034A2 (en) | 1993-04-06 | 1994-10-13 | Cedars-Sinai Medical Center | Variant insulin-like growth factor i receptor subunits and methods for use thereof |
US20020022023A1 (en) | 1999-01-15 | 2002-02-21 | Axel Ullrich | Treatment of diabetes mellitus and insulin receptor signal transduction |
AUPM672594A0 (en) | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
US6084085A (en) | 1995-11-14 | 2000-07-04 | Thomas Jefferson University | Inducing resistance to tumor growth with soluble IGF-1 receptor |
US6346390B1 (en) | 1996-03-08 | 2002-02-12 | Receptron, Inc. | Receptor derived peptides involved in modulation of response to ligand binding |
US5958872A (en) | 1996-04-01 | 1999-09-28 | Apoptosis Technology, Inc. | Active survival domains of IGF-IR and methods of use |
US20020107187A1 (en) | 1996-05-22 | 2002-08-08 | Kingston David J. | Modulating the activity of hormones or their receptors - peptides, antibodies, vaccines and uses thereof |
AUPN999096A0 (en) | 1996-05-22 | 1996-06-13 | Northstar Biologicals Pty Ltd | Peptides, antibodies, vaccines & uses thereof |
EP0932679A1 (de) | 1996-10-18 | 1999-08-04 | CANJI, Inc. | Verfahren und zusammensetzungen zur verabreichung und expression von interferon-alpha nukleinsäuren |
US20020155095A1 (en) | 1996-10-18 | 2002-10-24 | Tattanahalli L. Nagabhushan | Methods and compositions for delivery and expression of interferon-a nucleic acids |
AU5451598A (en) | 1996-11-22 | 1998-06-10 | Regents Of The University Of California, The | Transport of liposomes across the blood-brain barrier |
US6294330B1 (en) | 1997-01-31 | 2001-09-25 | Odyssey Pharmaceuticals Inc. | Protein fragment complementation assays for the detection of biological or drug interactions |
US6121416A (en) | 1997-04-04 | 2000-09-19 | Genentech, Inc. | Insulin-like growth factor agonist molecules |
DE19719001C2 (de) | 1997-05-06 | 2001-05-10 | Schuetzdeller Angelika | Verfahren zum immunologisch-funktionalen Nachweis biologisch aktiver Insulin-Like Growth Factor Binding Proteine oder löslicher Insulin-Like Growth Factor - Rezeptoren im Immunoassay |
CN1294517A (zh) | 1997-11-14 | 2001-05-09 | 欧洲细胞技术有限公司 | 具有合成可变区和修饰特异性的免疫球蛋白分子 |
JP2001525339A (ja) | 1997-11-27 | 2001-12-11 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション | Igf受容体に対するアゴニストおよびアンタゴニストの設計方法 |
AU2783099A (en) | 1998-02-24 | 1999-09-06 | Receptron, Inc. | Receptor derived peptides as modulators of receptor activity |
ZA200007412B (en) | 1998-05-15 | 2002-03-12 | Imclone Systems Inc | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases. |
CA2332331A1 (en) | 1998-05-15 | 1999-11-25 | Francisco Robert | Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases |
GB9818110D0 (en) | 1998-08-19 | 1998-10-14 | Weston Medical Ltd | Needleless injectors and other devices |
US7173005B2 (en) | 1998-09-02 | 2007-02-06 | Antyra Inc. | Insulin and IGF-1 receptor agonists and antagonists |
US6875741B2 (en) | 1998-09-02 | 2005-04-05 | Renuka Pillutla | Insulin and IGF-1 receptor agonists and antagonists |
US20030236190A1 (en) | 1998-09-02 | 2003-12-25 | Renuka Pillutla | Isulin and IGF-1 receptor agonists and antagonists |
DE69938190T2 (de) | 1998-10-15 | 2009-03-05 | Novartis Vaccines and Diagnostics, Inc., Emeryville | Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen |
US6096002A (en) | 1998-11-18 | 2000-08-01 | Bioject, Inc. | NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method |
AU3579200A (en) | 1999-02-26 | 2000-09-14 | Saltech I Goteborg Ab | Method and composition for the regulation of hepatic and extrahepatic productionof insulin-like growth factor-1 |
US6316462B1 (en) | 1999-04-09 | 2001-11-13 | Schering Corporation | Methods of inducing cancer cell death and tumor regression |
WO2000069454A1 (en) | 1999-05-17 | 2000-11-23 | Board Of Regents, The University Of Texas System | Suppression of endogenous igfbp-2 to inhibit cancer |
WO2001007084A1 (en) | 1999-07-23 | 2001-02-01 | Regents Of The University Of California | Anti-growth factor receptor avidin fusion proteins as universal vectors for drug delivery |
WO2001030964A2 (en) | 1999-10-22 | 2001-05-03 | Lifespan Biosciences, Inc. | Anti-cancer nucleic acid and protein targets |
AU1410801A (en) | 1999-11-17 | 2001-05-30 | Compugen Ltd. | Variants of alternative splicing |
WO2001044464A1 (en) | 1999-12-15 | 2001-06-21 | Mcgill University | Targeting of endosomal growth factor processing as anti-cancer therapy |
AU2001245888A1 (en) | 2000-03-21 | 2001-10-03 | University Of South Florida | Growth factor binding molecules |
EP1265635A1 (de) | 2000-03-22 | 2002-12-18 | Glaxo Group Limited | Arzneimittel bestehend aus einem zellzyklus-blockierenden mittel und einem antikörper |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
JP2004512010A (ja) | 2000-03-29 | 2004-04-22 | ディージーアイ・バイオテクノロジーズ・エル・エル・シー | インスリン及びigf−1受容体のアゴニスト及びアンタゴニスト |
WO2001075064A2 (en) | 2000-03-31 | 2001-10-11 | Hyseq, Inc. | Method and materials relating to insulin-like growth factor binding protein-like polypeptides and polynucleotides |
US6372250B1 (en) | 2000-04-25 | 2002-04-16 | The Regents Of The University Of California | Non-invasive gene targeting to the brain |
US7329745B2 (en) | 2000-06-13 | 2008-02-12 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
US20030165502A1 (en) | 2000-06-13 | 2003-09-04 | City Of Hope | Single-chain antibodies against human insulin-like growth factor I receptor: expression, purification, and effect on tumor growth |
US20020164333A1 (en) | 2000-07-10 | 2002-11-07 | The Scripps Research Institute | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
WO2002004522A2 (en) | 2000-07-10 | 2002-01-17 | Novartis Ag | Bifunctional molecules and vectors complexed therewith for targeted gene delivery |
WO2002007783A2 (en) | 2000-07-20 | 2002-01-31 | Regents Of The University Of Minnesota | Radiolabeled immunotoxins |
US20030162230A1 (en) | 2000-09-27 | 2003-08-28 | Reagan Kevin J. | Method for quantifying phosphokinase activity on proteins |
US8153121B2 (en) | 2000-10-06 | 2012-04-10 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Diagnosis and therapy of antibody-mediated inflammatory autoimmune disorders |
DE10050338A1 (de) | 2000-10-11 | 2002-04-25 | Deutsches Krebsforsch | Auf dem Nachweis von IGF-IRbeta und IRS-1 beruhendes Diagnose- bzw. Klassifizierungsverfahren für Carcinome |
EP1325341A2 (de) | 2000-10-12 | 2003-07-09 | Icos Corporation | Modulierung von ligandbindung/enzymatischer wirksamkeit von alpha- beta- proteinen |
AU2002236572A1 (en) | 2000-11-03 | 2002-05-21 | Board Of Regents, The University Of Texas System | Methods for detecting the efficacy of anticancer treatments |
WO2002043758A2 (en) | 2000-12-01 | 2002-06-06 | Schering Corporation | Uses of mammalian genes and related reagents |
WO2002054066A2 (en) | 2000-12-14 | 2002-07-11 | The Burnham Institute | Non-apoptotic forms of cell death and methods of modulation |
WO2002053596A2 (en) | 2001-01-05 | 2002-07-11 | Pfizer Inc. | Antibodies to insulin-like growth factor i receptor |
EP1395669B1 (de) | 2001-01-26 | 2009-07-22 | Selexis S.A. | Matrix-anheftungsregionen und verfahren zu deren verwendung |
US7071300B2 (en) | 2001-03-14 | 2006-07-04 | Genentech, Inc. | IGF antagonist peptides |
FR2824076B1 (fr) | 2001-04-27 | 2003-06-13 | Centre Nat Rech Scient | Methode de detection de composes activateurs ou inhibiteurs des recepteurs de la famille du recepteur de l'insuline au moyen d'un recepteur chimere isole |
WO2002087618A1 (fr) | 2001-04-27 | 2002-11-07 | Takeda Chemical Industries, Ltd. | Methode de prevention et de traitement du cancer |
WO2002100326A2 (en) | 2001-05-01 | 2002-12-19 | The General Hospital Corporation | Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies |
AR035885A1 (es) | 2001-05-14 | 2004-07-21 | Novartis Ag | Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica |
ATE440869T1 (de) | 2001-06-20 | 2009-09-15 | Fibron Ltd | Fgfr3 blockierende antikírper, verfahren zum screening darauf und verwendungen davon |
US20050037445A1 (en) | 2001-06-25 | 2005-02-17 | Poulsen Hans Skovgaard | Oncology drug innovation |
WO2003014696A2 (en) | 2001-08-06 | 2003-02-20 | Stil Biotechnologies Ltd. | Methods of identifying functional analogs of peptide regulators of biological pathways |
AUPR870501A0 (en) | 2001-11-07 | 2001-11-29 | Biotech Research Ventures Pte Limited | Composition containing a flavonoid glycone and method for using same as anti-proliferative |
US7241444B2 (en) | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
US7553485B2 (en) | 2002-01-18 | 2009-06-30 | Pierre Fabre Medicament | Anti-IGF-IR and/or anti-insulin/IGF-I hybrid receptors antibodies and uses thereof |
JP4606739B2 (ja) | 2002-01-18 | 2011-01-05 | ピエール、ファーブル、メディカマン | 新規抗igf−ir抗体およびその使用 |
FR2834990A1 (fr) | 2002-01-18 | 2003-07-25 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
FR2834900B1 (fr) | 2002-01-18 | 2005-07-01 | Pf Medicament | Nouvelles compositions a activite anti-igf-ir et anti-egfr et leurs applications |
FR2834991B1 (fr) | 2002-01-18 | 2004-12-31 | Pf Medicament | Nouveaux anticorps anti-igf-ir et leurs applications |
EP1497461A4 (de) | 2002-04-15 | 2007-06-06 | Rigel Pharmaceuticals Inc | Verfahren zum testen auf zellzyklusmodulatoren |
US7655397B2 (en) | 2002-04-25 | 2010-02-02 | The United States Of America As Represented By The Department Of Health And Human Services | Selections of genes and methods of using the same for diagnosis and for targeting the therapy of select cancers |
DE60329589D1 (de) | 2002-04-30 | 2009-11-19 | Kyowa Hakko Kirin Co Ltd | Antikörper gegen den humanen "insulin-like" wachstumsfaktor |
US7485314B2 (en) | 2002-05-06 | 2009-02-03 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Induction of antigen specific immunologic tolerance |
JP4563171B2 (ja) | 2002-05-24 | 2010-10-13 | シェーリング コーポレイション | 中和ヒト抗igfr抗体 |
GB0212303D0 (en) | 2002-05-28 | 2002-07-10 | Isis Innovation | Molecular targetting of IGF-1 receptor |
US8034904B2 (en) | 2002-06-14 | 2011-10-11 | Immunogen Inc. | Anti-IGF-I receptor antibody |
US7538195B2 (en) | 2002-06-14 | 2009-05-26 | Immunogen Inc. | Anti-IGF-I receptor antibody |
WO2004007673A2 (en) | 2002-07-12 | 2004-01-22 | The Johns Hopkins University | Neuronal gene expression patterns |
US20040142381A1 (en) | 2002-07-31 | 2004-07-22 | Hubbard Stevan R. | Methods for designing IGF1 receptor modulators for therapeutics |
US20040047835A1 (en) | 2002-09-06 | 2004-03-11 | Cell Therapeutics, Inc. | Combinatorial drug therapy using polymer drug conjugates |
US20030138430A1 (en) | 2002-09-20 | 2003-07-24 | Stimmel Julie Beth | Pharmaceutical comprising an agent that blocks the cell cycle and an antibody |
TW200501960A (en) | 2002-10-02 | 2005-01-16 | Bristol Myers Squibb Co | Synergistic kits and compositions for treating cancer |
US20040102360A1 (en) | 2002-10-30 | 2004-05-27 | Barnett Stanley F. | Combination therapy |
US20060281130A1 (en) | 2002-12-20 | 2006-12-14 | Elisabeth Bock | Metod of modulation of interaction between receptor and ligand |
JP2006517581A (ja) * | 2003-02-13 | 2006-07-27 | ファイザー・プロダクツ・インク | 抗インスリン様増殖因子i受容体抗体の使用 |
EP1603948A1 (de) * | 2003-03-14 | 2005-12-14 | Pharmacia Corporation | Antikörper gegen den igf-1 rezeptor zur behandlung von krebs |
ES2383014T3 (es) | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
US20050043233A1 (en) | 2003-04-29 | 2005-02-24 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis |
WO2005016970A2 (en) * | 2003-05-01 | 2005-02-24 | Imclone Systems Incorporated | Fully human antibodies directed against the human insulin-like growth factor-1 receptor |
AR046071A1 (es) | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
UA85058C2 (ru) | 2003-08-13 | 2008-12-25 | Пфайзер Продактс Инк. | Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir) |
DE10348391B3 (de) | 2003-10-17 | 2004-12-23 | Beru Ag | Verfahren zum Glühen einer Glühkerze für einen Dieselmotor |
CN1938428A (zh) | 2003-11-12 | 2007-03-28 | 先灵公司 | 多基因表达的质粒系统 |
TW200526684A (en) * | 2003-11-21 | 2005-08-16 | Schering Corp | Anti-IGFR1 antibody therapeutic combinations |
CA2564538A1 (en) | 2004-04-22 | 2005-12-01 | Oregon Health And Science University | Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors |
CA2569277A1 (en) | 2004-06-04 | 2005-12-15 | Pfizer Products Inc. | Method for treating abnormal cell growth |
EP2322215A3 (de) | 2004-07-16 | 2011-09-28 | Pfizer Products Inc. | Kombinationsbehandlung für nicht-hämatologische bösartige Erkrankungen mit einem anti-IGF-1R-Antikörper |
EP1786918A4 (de) | 2004-07-17 | 2009-02-11 | Imclone Systems Inc | Neuer tetravalenter bispezifischer antikörper |
FR2873699B1 (fr) | 2004-07-29 | 2009-08-21 | Pierre Fabre Medicament Sa | Nouveaux anticorps anti igf ir rt leurs utilisations |
US20060205810A1 (en) | 2004-11-24 | 2006-09-14 | Schering Corporation | Platinum therapeutic combinations |
JP4875064B2 (ja) * | 2005-04-15 | 2012-02-15 | シェーリング コーポレイション | 癌を処置または予防するための方法および組成物 |
EA200702239A1 (ru) | 2005-04-15 | 2008-10-30 | Иммьюноджен, Инк. | Уничтожение гетерогенной или смешанной клеточной популяции в опухолях |
US20060286103A1 (en) | 2005-06-15 | 2006-12-21 | Parag Kolhe | Stable antibody formulation |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
WO2007093008A1 (en) | 2006-02-17 | 2007-08-23 | Adelaide Research & Innovation Pty Ltd | Antibodies to insulin-like growth factor i receptor |
EP2405270B1 (de) | 2006-06-30 | 2013-07-17 | Merck Sharp & Dohme Corp. | IGFBP2-Biomarker |
-
2005
- 2005-11-30 CA CA002589885A patent/CA2589885A1/en not_active Abandoned
- 2005-11-30 DE DE602005025685T patent/DE602005025685D1/de active Active
- 2005-11-30 EP EP05852441A patent/EP1828249B1/de active Active
- 2005-11-30 MX MX2007006640A patent/MX2007006640A/es active IP Right Grant
- 2005-11-30 AT AT05852441T patent/ATE493442T1/de not_active IP Right Cessation
- 2005-11-30 WO PCT/US2005/043184 patent/WO2006060419A2/en active Application Filing
- 2005-11-30 JP JP2007544441A patent/JP2008521907A/ja not_active Withdrawn
- 2005-11-30 US US11/290,687 patent/US7811562B2/en not_active Expired - Fee Related
- 2005-11-30 EP EP10184355.5A patent/EP2281841A3/de not_active Withdrawn
- 2005-11-30 ES ES05852441T patent/ES2356830T3/es active Active
- 2005-11-30 EP EP10185346.3A patent/EP2283831A3/de not_active Withdrawn
- 2005-11-30 PT PT05852441T patent/PT1828249E/pt unknown
- 2005-12-01 TW TW094142319A patent/TWI376233B/zh active
-
2011
- 2011-05-13 JP JP2011108837A patent/JP2011157397A/ja active Pending
- 2011-12-21 JP JP2011280276A patent/JP2012067124A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
EP2281841A3 (de) | 2013-10-23 |
EP2283831A2 (de) | 2011-02-16 |
WO2006060419A2 (en) | 2006-06-08 |
JP2011157397A (ja) | 2011-08-18 |
EP2283831A3 (de) | 2013-10-23 |
EP1828249B1 (de) | 2010-12-29 |
DE602005025685D1 (de) | 2011-02-10 |
JP2012067124A (ja) | 2012-04-05 |
WO2006060419A9 (en) | 2006-07-20 |
US7811562B2 (en) | 2010-10-12 |
PT1828249E (pt) | 2011-02-25 |
US20060140960A1 (en) | 2006-06-29 |
CA2589885A1 (en) | 2006-06-08 |
WO2006060419A3 (en) | 2006-08-24 |
TWI376233B (en) | 2012-11-11 |
MX2007006640A (es) | 2007-06-19 |
TW200626174A (en) | 2006-08-01 |
ES2356830T3 (es) | 2011-04-13 |
EP2281841A2 (de) | 2011-02-09 |
JP2008521907A (ja) | 2008-06-26 |
EP1828249A2 (de) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE493442T1 (de) | Biologische marker zur vorauswahl von patienten für die anti-igf1r-therapie | |
ATE535529T1 (de) | Verfahren zur acylierung von maytansinol mit chiralen aminosäuren | |
RU2015125332A (ru) | Способы профилактики метастазирования опухолей, лечения и прогнозирования рака и идентификации агентов, которые являются предполагаемыми ингибиторами метастазирования | |
ATE485517T1 (de) | Verfahren zur identifizierung von polypeptid- targets | |
DE60029092D1 (de) | Verfahren zur detektion von nukleinsäuren, welche auf krebs hinweisen | |
UA93989C2 (ru) | Способ прогнозирования otbeta ha лечение | |
DE602005004354D1 (de) | Verfahren zur Lokalisierung von Fluoreszenzmarkers | |
ATE523786T1 (de) | In-vitro-verfahren zur prognose des fortschreitens einer krebserkrankung und des ausgangs für einen patienten sowie verfahren zur durchführung des verfahrens | |
DE602005027700D1 (de) | Verfahren zur nukleinsäureimmobilisierung | |
DE602004027600D1 (de) | Genexpressionsmarker für die prognose von brustkrebs | |
DE602005026386D1 (de) | Antisense-oligonukleotide zur induktion von exon-skipping sowie verfahren zur verwendung davon | |
DE60042695D1 (de) | Verfahren für den nachweis von erkrankungen | |
ATE397676T1 (de) | Identifikation und verwendung von mirnas zur differenzierung myelogener leukämiezellen | |
WO2008088854A3 (en) | Genetic markers for predicting responsiveness to combination therapy | |
TW200636076A (en) | Method for measuring resistance or sensitivity to docetaxel | |
ATE519862T1 (de) | Zusammensetzungen, kits und verfahren zur identifizierung, beurteilung, vorbeugung und therapie von gebärmutterhalskrebs | |
DE602007001103D1 (de) | Verfahren zur identifizierung von lrrk2 interagierenden molekülen und zur reinigung von lrrk2 | |
DE602004015626D1 (de) | Bei brustkrebs | |
DE602006013333D1 (de) | Kit und verfahren zum nachweis von urothelkarzinom | |
DE60326748D1 (de) | Verfahren zur identifizierung des brustkrebsrisikos | |
WO2009019370A3 (fr) | Procede de dosage de l'apolipoproteine aii pour le diagnostic in vitro du cancer colorectal | |
DE602005017252D1 (de) | Verfahren zur amplifikation von nukleinsäuren mittels promotor-templates | |
ATE545867T1 (de) | I-plastin-testverfahren zur in-vitro-diagnose von kolorektalkarzinom | |
DE602004030041D1 (de) | Verfahren und zusammensetzungen zur identifikation von rna-bindenden proteinen | |
ATE534902T1 (de) | Replikationsproteinn ciz1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |